Structure via PubChem · Public domain (PubChem)
tirbanibulin
Sign in to saveAlso known as KX-01, Klisyri, KX01
Tirbanibulin, sold under the brand name Klisyri, is a medication used for the treatment of actinic keratosis (AK) on the face or scalp. It functions by inhibiting both tubulin polymerization and Src kinase signaling. It is potentially effective in impeding the development of squamous cell carcinoma in situ.
Chemical data
- Formula
- C26H29N3O3
- Molecular weight
- 431.5 g/mol
- IUPAC name
- N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]-2-pyridinyl]acetamide
- SMILES
- C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
- InChIKey
- HUNGUWOZPQBXGX-UHFFFAOYSA-N
- XLogP
- 2.9
- Polar surface area
- 63.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- topical
- Indications
- acute myeloid leukemia, actinic keratosis, lymphoma, prostate cancer
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 431.220891788
- Has use
- medication
Show 3 more facts
- chemical formula
- C₂₆H₂₉N₃O₃
- canonical SMILES
- C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
- Commons category
- Tirbanibulin
Sources (1)
via Wikidata · CC0
~3 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Mechanism of Action
- Side effects
- History
- Society and culture
- Legal status
- References
- External links
Tirbanibulin, sold under the brand name Klisyri, is a medication used for the treatment of actinic keratosis (AK) on the face or scalp. It functions by inhibiting both tubulin polymerization and Src kinase signaling. It is potentially effective in impeding the development of squamous cell carcinoma in situ.
The most common side effects include local skin reactions, application site pruritus, and application site pain.
Excerpted from Wikipedia’s “tirbanibulin” article, available under the CC BY-SA 4.0 licence.